Evidence map›Paper›PMID 35170221›Full record

ArticleJournal of thrombosis and haemostasis : JTH2022

A novel nonsense variant in TPM4 caused dominant macrothrombocytopenia, mild bleeding tendency and disrupted cytoskeleton remodeling.

Ana Marín-Quílez, Elena Vuelta, Lorena Díaz-Ajenjo, Cristina Fernández-Infante, Ignacio García-Tuñón, Rocío Benito, Verónica Palma-Barqueros, Jesús María Hernández-Rivas, José Ramón González-Porras, José Rivera and 1 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ana Marín-QuílezIBSAL, CIC, IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain.ORCID 0000-0002-2005-1919
Elena VueltaIBSAL, CIC, IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain.
Lorena Díaz-AjenjoIBSAL, CIC, IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain.
Cristina Fernández-InfanteIBSAL, CIC, IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain.
Ignacio García-TuñónIBSAL, CIC, IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain.
Rocío BenitoIBSAL, CIC, IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain.
Verónica Palma-BarquerosDepartment of Hematology and Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain.
Jesús María Hernández-RivasIBSAL, CIC, IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain.
José Ramón González-PorrasDepartment of Hematology, Complejo Asistencial Universitario de Salamanca (CAUSA), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca (USAL), Salamanca, Spain.
José RiveraDepartment of Hematology and Oncology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain.
José María BastidaDepartment of Hematology, Complejo Asistencial Universitario de Salamanca (CAUSA), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca (USAL), Salamanca, Spain.ORCID 0000-0002-8007-3909
Universidad de Salamanca · ESCentro Regional de Hemodonación · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRare inherited thrombocytopenias are caused by alterations in genes involved in megakaryopoiesis, thrombopoiesis and/or platelet release. Diagnosis is challenging due to poor specificity of platelet laboratory assays, large numbers of culprit genes, and difficult assessment of the pathogenicity of novel variants.

objectivesTo characterize the clinical and laboratory phenotype, and identifying the underlying molecular alteration, in a pedigree with thrombocytopenia of uncertain etiology. PATIENTS/

methodsIndex case was enrolled in our Spanish multicentric project of inherited platelet disorders due to lifelong thrombocytopenia and bleeding. Bleeding score was recorded by ISTH-BAT. Laboratory phenotyping consisted of blood cells count, blood film, platelet aggregation and flow cytometric analysis. Genotyping was made by whole-exome sequencing (WES). Cytoskeleton proteins were analyzed in resting/spreading platelets by immunofluorescence and immunoblotting.

resultsFive family members displayed lifelong mild thrombocytopenia with a high number of enlarged platelets in blood film, and mild bleeding tendency. Patient's platelets showed normal aggregation and granule secretion response to several agonists. WES revealed a novel nonsense variant (c.322C>T; p.Gln108*) in TPM4 (NM_003290.3), the gene encoding for tropomyosin-4 (TPM4). This variant led to impairment of platelet spreading capacity after stimulation with TRAP-6 and CRP, delocalization of TPM4 in activated platelets, and significantly reduced TPM4 levels in platelet lysates. Moreover, the index case displayed up-regulation of TPM2 and TPM3 mRNA levels.

conclusionsThis study identifies a novel TPM4 nonsense variant segregating with macrothrombocytopenia and impaired platelet cytoskeletal remodeling and spreading. These findings support the relevant role of TPM4 in thrombopoiesis and further expand our knowledge of TPM4-related thrombocytopenia.

Indexed as

Blood Platelet DisordersThrombocytopeniaBlood PlateletsCytoskeletonHemorrhageHumansThrombopoiesisTropomyosinTPM4 protein, humanTropomyosininherited platelet disordersmacrothrombocytopeniaTPM4tropomyosin-4whole-exome sequencing

Identifiers

PMID35170221
PMCPMC9306899
OpenAlexW4213065766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.